83_FR_59615 83 FR 59389 - National Institute on Drug Abuse; Notice of Closed Meetings

83 FR 59389 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 226 (November 23, 2018)

Page Range59389-59389
FR Document2018-25427

Federal Register, Volume 83 Issue 226 (Friday, November 23, 2018) 
[Federal Register Volume 83, Number 226 (Friday, November 23, 2018)]
[Notices]
[Page 59389]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-25427]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; NIDA Research Education Program for Clinical 
Researchers and Clinicians (R25).
    Date: November 27, 2018.
    Time: 10:00 a.m. to 12:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 
301-827-5840, [email protected].
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Multi-Site Studies for System-Level Implementation 
of Substance Use Prevention and Treatment Services (R01; R34).
    Date: November 27, 2018.
    Time: 1:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 
301-827-5840, [email protected].
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Workshops on the Use of Adolescent Brain Cognitive 
Development (ABCD) Data (R25 Clinical Trial Not Allowed).
    Date: November 29, 2018.
    Time: 10:00 a.m. to 11:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 
301-827-5840, [email protected].
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research 
(R21 Clinical Trial Optional).
    Date: December 5, 2018.
    Time: 12:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Advancing Exceptional Research on HIV/AIDS and 
Substance Abuse (R01, Clinical Trial Optional).
    Date: December 13, 2018.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, 
Bethesda, MD 20892-9550, 301-827-5819, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)


    Dated: November 16, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25427 Filed 11-21-18; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 226 / Friday, November 23, 2018 / Notices 59389 Public attendance at the meeting is Contact Person: Julia Berzhanskaya, Ph.D., Extramural Policy and Review, National limited to the available space. Scientific Review Officer, Office of Institute on Drug Abuse, National Institutes Individuals who plan to attend and Extramural Policy and Review, Division of of Health, DHHS, 6001 Executive Boulevard, Extramural Research, National Institute on Room 4238, MSC 9550, Bethesda, MD 20892, need special assistance, such as sign Drug Abuse, NIH, DHHS, 6001 Executive 301–827–5820, hiromi.ono@nih.gov. language interpretation or other Boulevard, Room 4234, MSC 9550, Bethesda, Name of Committee: National Institute on reasonable accommodations, should MD 20892, 301–827–5840, Drug Abuse Special Emphasis Panel; notify the Advisory Council at the julia.berzhanskaya@nih.gov. Advancing Exceptional Research on HIV/ address/telephone number listed above This notice is being published less than 15 AIDS and Substance Abuse (R01, Clinical at least one week prior to the meeting. days prior to the meeting due to the timing Trial Optional). For those unable to attend in person, a limitations imposed by the review and Date: December 13, 2018. live webcast will be available. More funding cycle. Time: 12:00 p.m. to 4:00 p.m. information on registration and Name of Committee: National Institute on Agenda: To review and evaluate grant Drug Abuse Special Emphasis Panel; Multi- applications. accessing the webcast can be found at Place: National Institutes of Health, Site Studies for System-Level http://www.hhs.gov/ash/carb/. Implementation of Substance Use Prevention Neuroscience Center, 6001 Executive Members of the public will have the and Treatment Services (R01; R34). Boulevard, Rockville, MD 20852 (Telephone opportunity to provide comments prior Date: November 27, 2018. Conference Call). to the Advisory Council meeting by Time: 1:00 p.m. to 4:30 p.m. Contact Person: Gerald L. McLaughlin, emailing CARB@hhs.gov. Public Agenda: To review and evaluate grant Ph.D., Scientific Review Officer, Office of comments should be sent in by applications. Extramural Policy and Review, National midnight January 23, 2019, and should Place: National Institutes of Health, Institute on Drug Abuse, NIH, DHHS, 6001 be limited to no more than one page. All Neuroscience Center, 6001 Executive Executive Blvd., Room 4238, MSC 9550, Boulevard, Rockville, MD 20852 (Telephone Bethesda, MD 20892–9550, 301–827–5819, public comments received prior to gm145a@nih.gov. Conference Call). January 23, 2019, will be provided to Contact Person: Julia Berzhanskaya, Ph.D., (Catalogue of Federal Domestic Assistance Advisory Council members; comments Scientific Review Officer, Office of Program Nos.: 93.279, Drug Abuse and are limited to five minutes per speaker. Extramural Policy and Review, Division of Addiction Research Programs, National Dated: November 16, 2018. Extramural Research, National Institute on Institutes of Health, HHS) Drug Abuse, NIH, DHHS, 6001 Executive Tammy R. Beckham, Boulevard, Room 4234, MSC 9550, Bethesda, Dated: November 16, 2018. Acting Director, National Vaccine Program MD 20892, 301–827–5840, Natasha M. Copeland, Office. julia.berzhanskaya@nih.gov. Program Analyst, Office of Federal Advisory [FR Doc. 2018–25439 Filed 11–21–18; 8:45 am] This notice is being published less than 15 Committee Policy. BILLING CODE 4150–44–P days prior to the meeting due to the timing limitations imposed by the review and [FR Doc. 2018–25427 Filed 11–21–18; 8:45 am] funding cycle. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND Name of Committee: National Institute on HUMAN SERVICES Drug Abuse Special Emphasis Panel; Workshops on the Use of Adolescent Brain DEPARTMENT OF HEALTH AND National Institutes of Health Cognitive Development (ABCD) Data (R25 HUMAN SERVICES Clinical Trial Not Allowed). National Institute on Drug Abuse; Date: November 29, 2018. National Institutes of Health Notice of Closed Meetings Time: 10:00 a.m. to 11:30 a.m. Agenda: To review and evaluate grant National Institute on Drug Abuse; Pursuant to section 10(d) of the applications. Notice of Closed Meeting Federal Advisory Committee Act, as Place: National Institutes of Health, amended, notice is hereby given of the Neuroscience Center, 6001 Executive Pursuant to section 10(d) of the following meetings. Boulevard, Rockville, MD 20852 (Telephone Federal Advisory Committee Act, as The meetings will be closed to the Conference Call). amended, notice is hereby given of the Contact Person: Julia Berzhanskaya, Ph.D., following meeting. public in accordance with the Scientific Review Officer, Office of provisions set forth in sections The meeting will be closed to the Extramural Policy and Review, Division of public in accordance with the 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Extramural Research, National Institute on as amended. The grant applications and Drug Abuse, NIH, DHHS, 6001 Executive provisions set forth in sections the discussions could disclose Boulevard, Room 4234, MSC 9550, Bethesda, 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., confidential trade secrets or commercial MD 20892, 301–827–5840, as amended. The contract proposals and property such as patentable material, julia.berzhanskaya@nih.gov. the discussions could disclose and personal information concerning This notice is being published less than 15 confidential trade secrets or commercial days prior to the meeting due to the timing property such as patentable material, individuals associated with the grant limitations imposed by the review and applications, the disclosure of which and personal information concerning funding cycle. individuals associated with the contract would constitute a clearly unwarranted Name of Committee: National Institute on invasion of personal privacy. proposals, the disclosure of which Drug Abuse Special Emphasis Panel; would constitute a clearly unwarranted Name of Committee: National Institute on Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional). invasion of personal privacy. Drug Abuse Special Emphasis Panel; NIDA Research Education Program for Clinical Date: December 5, 2018. Name of Committee: National Institute on Researchers and Clinicians (R25). Time: 12:00 p.m. to 2:00 p.m. Drug Abuse Special Emphasis Panel; amozie on DSK3GDR082PROD with NOTICES1 Date: November 27, 2018. Agenda: To review and evaluate grant Pharmacokinetic Analysis Resource Center Time: 10:00 a.m. to 12:30 p.m. applications. (8947). Agenda: To review and evaluate grant Place: National Institutes of Health, Date: January 8, 2019. applications. Neuroscience Center, 6001 Executive Time: 11:00 a.m. to 1:00 p.m. Place: National Institutes of Health, Boulevard, Rockville, MD 20852 (Telephone Agenda: To review and evaluate contract Neuroscience Center, 6001 Executive Conference Call). proposals. Boulevard, Rockville, MD 20852 (Telephone Contact Person: Hiromi Ono, Ph.D., Place: National Institutes of Health, Conference Call). Scientific Review Officer, Office of Neuroscience Center, 6001 Executive VerDate Sep<11>2014 18:33 Nov 21, 2018 Jkt 247001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 E:\FR\FM\23NON1.SGM 23NON1


Document Created: 2018-11-27 12:59:00
Document Modified: 2018-11-27 12:59:00
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesNovember 27, 2018.
FR Citation83 FR 59389 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR